NCT07407803 is a Phase 3 clinical trial of TQ-B3234 capsules in Plexiform Neurofibroma, sponsored by Chia Tai Tianqing Pharmaceutical Group Co., Ltd..

Who is sponsoring NCT07407803?

NCT07407803 is sponsored by Chia Tai Tianqing Pharmaceutical Group Co., Ltd..

What drugs are being tested in NCT07407803?

Interventions in NCT07407803: TQ-B3234 capsules, TQ-B3234 placebo.

What condition does NCT07407803 study?

NCT07407803 studies Plexiform Neurofibroma.

Is NCT07407803 still recruiting?

NCT07407803 is currently recruiting now. Last updated 22 May 2026.

Last reviewed 2026-05-22 · How we verify

NCT07407803

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Randomized, Double-Blind, Parallel-Controlled, Multicenter Phase III Clinical Trial Evaluating the Efficacy and Safety of TQ-B3234 Capsules Versus Placebo in Patients With Symptomatic, Non-Surgical Type 1 Neurofibromatosis-Associated Plexiform Neurofibromas

Recruiting now Phase 3 Last updated 22 May 2026

What this trial tests

Phase 3 trial testing TQ-B3234 capsules in Plexiform Neurofibroma in 177 participants. Currently enrolling.

Timeline

31 March 2026

Primary endpoint
1 December 2027

1 December 2028

Quick facts

Lead sponsor	Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Phase	Phase 3
Status	Recruiting now
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	quadruple
Primary purpose	treatment
Enrollment	177
Start date	31 March 2026
Primary completion	1 December 2027
Estimated completion	1 December 2028
Sites	29 locations across China

Drugs / interventions tested

TQ-B3234 capsules — full drug profile →
TQ-B3234 placebo — full drug profile →

Conditions studied

Plexiform Neurofibroma — all drugs for Plexiform Neurofibroma →

Sponsor

Chia Tai Tianqing Pharmaceutical Group Co., Ltd. — full company profile →

Who can join

18 and older, any sex, with Plexiform Neurofibroma. Patients with the condition only — healthy volunteers not accepted.

What's being measured

Primary outcomes are the specific endpoints the trial is designed to prove or disprove.

IRC-Assessed Objective Response Rate (ORR)
Time frame: From subject enrollment to the end of cycle 24 (each cycle is 28 days)
Percentage of subjects achieving complete response (CR) or partial response (PR) as assessed by independent review committee (IRC) per REiNS criteria at the end of Cycle 24.

Sponsor's own description

This study aims to demonstrate that in subjects with symptomatic, inoperable plexiform neurofibromas associated with neurofibromatosis type 1, TQ-B3234 capsules significantly improve the objective response rate at Week 24 compared to placebo.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Plexiform Neurofibroma

Currently open trials in the same condition.

NCT06188741 — Selumetinib for the Prevention of Plexiform Neurofibroma Growth in NF Type 1 · Phase 2 · recruiting
NCT06104488 — A Study of Avutometinib for People With Solid Tumor Cancers · Phase 1 · recruiting
NCT05913037 — FCN-159 in Adult Patients With Symptomatic, Inoperable Neurofibromatosis Type 1-Related Plexiform Neurofibromas · Phase 3 · active not recruiting
NCT04954001 — Study to Evaluate the Safety, Tolerability, PK Characteristics and Anti-tumor Activity of FCN-159 in Adult and Pediatric · Phase 1, PHASE2 · active not recruiting
NCT03962543 — MEK Inhibitor Mirdametinib (PD-0325901) in Patients With Neurofibromatosis Type 1 Associated Plexiform Neurofibromas · Phase 2 · active not recruiting

Other Chia Tai Tianqing Pharmaceutical Group Co., Ltd. trials

Trials by the same sponsor.

NCT06990776 — A Clinical Trial to Evaluate the Efficacy and Safety of TQA3605 Tablets in Treatment-naive Chronic HBV-infected Subjects · Phase 2 · withdrawn
NCT06851442 — Clinical Trial of Evaluating TQB3912 Tablets Combined With Fulvestrant Injection±TQB3616 Capsules for Locally Advanced o · Phase 1, PHASE2 · terminated
NCT06711991 — A Clinical Trial of TQC3927 Powder for Inhalation in Chronic Obstructive Pulmonary Disease · Phase 1 · completed
NCT06672276 — To Evaluate the Pharmacokinetics and Safety of TQD3606 for Injection in Subjects With Renal Insufficiency · Phase 1 · completed
NCT06644417 — Clinical Study of TQA3605 Tablets Combined With Nucleoside (Acid) Analogs (NAs) Drugs Compared With NAs Drugs in the Tre · Phase 2 · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT07407803 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Last refreshed: 22 May 2026

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07407803.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing